Pulse Biosciences, Inc. (PLSE) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash cushion ⢠Revenue gap ⢠Cash burn PLSE has a strong cash-rich, low-debt balance sheet, but its tiny revenue base, heavy losses, ongoing cash burn, and extremely rich valuation make the stock fundamentally risky. #cash-richâ
Price Behavior
Key Price Behavior Insights: ⢠Higher price floor ⢠Upper-band rejection ⢠Momentum fading Support Level: $24.3 to $24.7 Resistance Level: $26.9 to $27.1 Over the last month, PLSE remains in a constructive uptrend with a higher price floor, but repeated stalls in the upper-$26 area and recent momentum loss mean it needs a decisive breakout above resistance to confirm the next leg higher.
Sentiment & News
Key News Insights: ⢠Atrial fibrillation focus ⢠Investor conference push ⢠Heavy insider buying Pulse Biosciences' headlines centered on advancing its nanosecond pulsed field ablation program, upcoming investor presentations, and strong insider buying that signals management confidence.
AI Summary
PLSE has shifted from a speculative nsPFA technology story to a high-stakes execution bet on whether nPulse can advance through the pivotal FDA path, with upside if clinical momentum continues but significant risk because the stock already reflects meaningful optimism and any slippage could trigger dilution or multiple compression.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |